close icon

AMD’s Crypto-Inspired Stock Chart Looks Promising

The biggest profits during the gold rush of the 19th century were made by those selling picks and shovels. Similarly, graphics cards providers are currently making a killing as the crypto mania inspires a lot of people to spend big on mining equipment. As Intel stock keeps tracking the Elliott Wave path, it is time to take a look at the price chart of Advanced Micro Devices Inc. or simply AMD.

amd stock elliott wave analysis

The daily chart of AMD stock visualizes its entire price development since the low at $1.61 in July, 2015. By late-February, 2017, the stock had climbed by as much as 866% to as high as $15.55. What interests us as Elliott Wave analysts is the fact that this impressive rally could be seen as a five-wave impulse, which comes to tell us that AMD is in an uptrend. However, every impulse is followed by a correction of three waves in the opposite direction. AMD’s corrective decline appears to be an A-B-C expanding flat correction with an ending diagonal in the position of wave C.

If this count is correct, the 5-3 wave cycle is complete and the trend is supposed to resume in the direction of the impulsive pattern. Wave (3/C) has the potential to exceed the top of wave (1/A), which means levels above $15.55 could be expected from now on, giving the stock 35% upside potential from current levels. Unless the Bitcoin bubble pops, of course.



Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

Shopify is One of Many Bubble Stocks Out There

It is becoming pretty clear that a speculative bubble is inflating right now. Money-losing companies with market caps in the tens and even hundreds of billions of dollars have become the norm, not the exception. People, who have been in the market for just a couple of months are bragging online about the phenomenal returns…

Read More »

Undervalued Bristol Myers Stock Can Still Get Cheaper

It’s been almost two years since we shared our bullish stance on Bristol Myers stock. Shares in the pharmaceutical major were changing hands for less than $46 in April, 2019. The company had just announced its planned acquisition of Celgene for about $74 billion and Wall Street apparently didn’t like the risks involved. However, the…

Read More »

DraftKings on the Verge of Another 40% Decline

It’s been almost three and a half months since we examined DraftKings stock in October, 2020. The share price was hovering near $57 after a strong run from $10.60 to over $64 in just several months. The regulatory environment in the U.S. seemed to be warming up and many analysts hurried to issue their BUY…

Read More »

AMN Healthcare Stock to Suffer a 2020-Like Drop

AMN Healthcare Services provides workforce and staffing solutions to healthcare facilities in the U.S. The company is relatively small with a market capitalization of less than $4 billion. However, small companies can make for excellent returns if one happens to identify the winners. And indeed, between late-2011 and early-2020, AMN stock from under $4 to…

Read More »

Zoetis Stock Getting Ahead of Itself, Invites Correction

Based in Parsippany, NJ, Zoetis Inc. is an animal medicine and vaccine developer and manufacturer. The company went public in 2013 and has been enjoying steady growth since. With the stock currently above $160 a share, Zoetis holds a market cap of nearly $80 billion. For a profitable and growing company like Zoetis, a rising…

Read More »

CBOE Stock Looking Good After a Record Year

CBOE Global Markets Inc. is an equities, options and futures exchange operator in the U.S. and Europe. The company traces its roots back to Chicago in 1973, when it practically invented options trading in its present form. CBOE is literally part of the very infrastructure of modern financial markets. So it is not surprising that…

Read More »

Novo Nordisk Bulls Have an Elliott Wave Problem

Novo Nordisk A/S is a Danish pharmaceuticals major with a market cap of over $160 billion. People need their medication even in recessions, so the company’s business wasn’t as affected by the 2020 crisis as most other industries. Novo Nordisk remains a top-notch pharma with consistent profits and revenue and no debt whatsoever. And the…

Read More »

More analyses